(NASDAQ CM: GTXI)
Attention investors who purchased shares of GTx, Inc. before March 7, 2019:
Rigrodsky & Long is investigating potential claims against the board of directors of GTx, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Oncternal Therapeutics, Inc.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of GTx, Inc. (“GTx” or the “Company”) (NASDAQ CM: GTXI) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to merge with Oncternal Therapeutics, Inc. (“Oncternal”). Under the terms of the agreement, current GTx stockholders will own approximately 25% of the combined company. In addition, GTx stockholders of record as of immediately prior to the effective time of the merger will receive non-transferable contingent value rights (“CVR”) entitling the holders to receive in the aggregate 50% of any net proceeds derived from the grant, sale or transfer of rights to SARD or SARM technology during the term of the CVR and, if applicable, to receive royalties on the sale of any SARD products by the combined company during the term of the CVR. The combined company is expected to trade on the NASDAQ Capital Market under a new ticker symbol, “ONCT.”
If you own common stock of GTx and purchased any shares before March 7, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at firstname.lastname@example.org, or at https://www.rigrodskylong.com/offices-contact.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.